Alector, Inc. (ALEC) Stock

Alector, Inc. (ALEC) is a Healthcare stock trading at $2.35 (as of 2026-08-21), with a market capitalization of $260.91M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Alector, Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, including humanized monoclonal antibody programs such as AL001 in Phase III and AL101 in Phase I, along with additional antibody candidates in earlier clinical phases. Its drug development targets conditions including frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis.

Understand Alector, Inc.: how it makes money

Alector develops clinical-stage therapies for neurodegeneration diseases, including a humanized monoclonal antibody (AL001, in Phase III) and other antibody candidates (AL101 in Phase I, AL002 in Phase II), and it makes money largely through limited collaboration revenue.

Because Alector is pre-commercial, its near-term profit model is mainly small collaboration revenue, while funding is largely consumed by continued clinical trial execution, reflected in very large operating losses.

Revenue by segment (latest quarter)
Collab$0.0B

Business quality (Weak): Data is directionally clear (clinical stage, minimal revenue, large operating losses), but segment coverage is limited to a small collaboration line, and total revenue is shown as 0.0B while collaboration revenue is 0.01B.

Bull case

  • Multiple programs across stages: AL001 is in Phase III clinical trial for frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, while AL101 is in Phase I and AL002 is in Phase II for neurodegenerative diseases.
  • Clinical trial execution metrics are tracked: INV OKE-2 Phase 2 shows measurable progress via participants enrolled and weeks of treatment.

Bear case

  • Material operating losses: For the latest quarter shown (2026-03-31), operating margin is -2382.3.
  • Minimal revenue base: Revenue is shown as 0.0B, with only small collaboration revenue reported (0.01B).
  • Cost pressure signaled by workforce reduction: Workforce Reduction is 17.0 percent, which can indicate efforts to manage cash needs during clinical development.
Valuation — source: SEC EDGAR (first-party)
Price$2.35
Market Cap$260.91M
Price / Sales30.09
FCF Yield-125.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$21.05M
Net Margin-679.2%
Revenue Growth (YoY)-79.1%
EPS Growth (YoY)13.0%
FCF Growth (YoY)-20.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-4.93 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderTCG Crossover Management, LLC ($21.50M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOArnon Rosenthal
Employees175
CountryUS
IPO Date2019-02-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Surrozen, Inc. (SRZN)
  • Lineage Cell Therapeutics, Inc. (LCTX)
  • Precision BioSciences, Inc. (DTIL)
  • Acumen Pharmaceuticals, Inc. (ABOS)
  • Coherus Oncology, Inc. (CHRS)
  • Protara Therapeutics, Inc. (TARA)
  • Voyager Therapeutics, Inc. (VYGR)
  • Protalix BioTherapeutics, Inc. (PLX)
ALEC earnings history · ALEC institutional & insider holders · ALEC KPIs & operating metrics · ALEC financials · ALEC investor presentations & press releases · ALEC SEC filings · ALEC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.